Quest joins breast cancer gene-testing market

Share this article:

Quest's new BRCA test may loosen Myriad's hold on the genetic cancer testing market. The diagnostics firm is now selling tests for the two cancer genes that are linked to breast and ovarian cancer—BRCA1 and BRCA2—and for which Medicare pays around $3,400 when using Myriad's version. Bloomberg reports that Quest plans on charging $2,500.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.